Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation

Cell Death and Disease

Volumn 7, Issue 8, 2016, Pages

  Bagnati, Marta ^a   Ogunkolade, Babatunji W ^a   Marshall, Catriona ^a   Tucci, Carmen ^b   Hanna, Katie ^b   Jones, Tania A ^a   Bugliani, Marco ^c   Nedjai, Belinda ^d   Caton, Paul W ^e   Kieswich, Julius ^a   Yaqoob, Muhammed M ^a   Ball, Graham R ^b   Marchetti, Piero ^c   Hitman, Graham A ^a   Turner, Mark D ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF PISA   (Italy)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; NUCLEIC ACID; OLEIC ACID; PALMITIC ACID; SMALL INTERFERING RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 5; UNCLASSIFIED DRUG; LIPID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; GLUCOLIPOTOXICITY; IMMUNOFLUORESCENCE; INFLAMMATION; INS-1 CELL LINE; LIPOTOXICITY; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE CULTURE CELL; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD40; CELL DEATH; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INSULIN-SECRETING CELLS; LIPIDS; MICE, INBRED C57BL; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 85016152356     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.203     Document Type: Article

References (42)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Mathis D, Vence L, Benoist C. Beta-Cell death during progression to diabetes. Nature 2001; 414: 792-798.
4. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-384.
5. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009; 24: 325-331.
6. Novotny GW, Lundh M, Backe MB, Christensen DP, Hansen JB, Dahllöf MS et al. Transcriptional and translational regulation of cytokine signaling in inflammatory β-cell dysfunction and apoptosis. Arch Biochem Biophys 2012; 528: 171-184.
7. Moore F, Naamane N, Colli ML, Bouckenooghe T, Ortis F, Gurzov EN et al. STAT1 is a master regulator of pancreatic β-cell apoptosis and islet inflammation. J Biol Chem 2011; 286: 929-941.
8. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA et al. Glucoseinduced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
9. Kepp O, Galluzzi L, Zitvogel L, Kroemer G. Pyroptosis - A cell death modality of its kind? Eur J Immunol 2010; 40: 627-630.
10. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
11. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008; 31: S161-S164.
12. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002; 51(Suppl3): S455-S461.
13. Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20: 143-148.
14. Janjic D, Maechler P, Sekine N, Bartley C, Annen AS, Wolheim CB. Free radical modulation of insulin release in INS-1 cells exposed to alloxan. Biochem Pharmacol 1999; 57: 639-648.
15. Maechler P, Wollheim CB. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999; 402: 685-689.
16. Pi J, Bai Y, Zhang Q, Wong V, Floering LM, Daniel K et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 2007; 56: 1783-1791.
17. Llanos P, Contreras-Ferrat A, Barrientos G, Valencia M, Mears D, Hidalgo C. Glucosedependent insulin secretion in pancreatic β-cell islets from male rats requires Ca2+ release via ROS-stimulated ryanodine receptors. Plos One 2015; 10: e0129238.
18. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742.
19. Nedjai B, Hitman GA, Yousaf N, Chernajovsky Y, Stjernberg-Salmela S, Pettersson T et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 273-283.
20. Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church LD, McDermott MF et al. Proinflammatory action of the antiinflammatory drug infliximab in TNF-receptor associated periodic syndrome. Arthritis Rheum 2009; 60: 619-625.
21. Nedjai B, Hitman GA, Church LD, Minden K, Whiteford ML, McKee S et al. Differential cytokine secretion resulting from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNFR-associated periodic fever syndrome patients. Cell Immunol 2011; 268: 55-59.
22. Arntfield M, van der Kooy D. The adult mammalian pancreas contains separate precursors of pancreatic and neural crest developmental origins. Stem Cells Dev 2013; 22: 2145-2157.
23. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci 2010; 101: 1073-1079.
24. Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 2010; 77: 197-213.
25. Klein D, Barbé-Tuana F, Pugliese A, Ichii H, Garza D, Gonzalez M et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005; 48: 268-276.
26. Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL. CD40 activation in human pancreatic islets and ductal cells. Diabetologia 2008; 51: 1853-1861.
27. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 2006; 55: 237-242.
28. Neubauer H, Setiadi P, Günesdogan B, Pinto A, Börgel J, Mügge A. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetes. Diabet Med 2010; 27: 384-390.
29. El-Asrar MA, Adly AA, Ismail EA. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatr Diabetes 2012; 13: 616-624.
30. Kirk AD, Knechtle SJ, Vincenti FG, Nadeau KC. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001; 1(suppl1): 191.
31. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. BG9588 Lupus Nephritis Trial Group. short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
32. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391-397.
33. Pree I, Wekerle T. New approaches to prevent transplant rejection: co-stimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today 2006; 3: 41-47.
34. Goldwater R, Keirns J, Blahunka P, First R, Sawamoto T, Zhang W et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant 2013; 13: 1040-1046.
35. Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 2014; 36: 96-104.
36. Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159: 58-66.
37. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 2136-2142.
38. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65: 5898-5906.
39. Marshall C, Hitman GA, Cassell PG, Turner MD. Effect of glucolipotoxicity and rosiglitazone upon insulin secretion. Biochem Biophys Res Comm 2007; 356: 756-762.
40. Marselli L, Suleiman M, Masini M, Campani D, Bugliani M, Syed F et al. Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia 2014; 57: 362-365.
41. Bugliani M, Liechti R, Cheon H, Suleiman M, Marselli L, Kirkpatrick C et al. Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitinproteasome system in pancreatic beta cell dysfunction. Mol Cell Endocrinol 2013; 367: 1-10.
42. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009; 37: D619-D622.